Rogers Corp. (ROG)

118.16
0.31 0.26
NYSE : Electronic Technology
Prev Close 117.85
Open 117.25
Day Low/High 117.25 / 119.18
52 Wk Low/High 105.60 / 184.00
Volume 33.77K
Avg Volume 120.20K
Exchange NYSE
Shares Outstanding 18.37M
Market Cap 2.16B
EPS 4.40
P/E Ratio 27.49
Div & Yield N.A. (N.A)

Latest News

Genentech Announces Submission Of Supplemental New Drug Application For Venclexta For People With Previously Untreated Acute Myeloid Leukemia Who Are Ineligible For Intensive Chemotherapy

Genentech Announces Submission Of Supplemental New Drug Application For Venclexta For People With Previously Untreated Acute Myeloid Leukemia Who Are Ineligible For Intensive Chemotherapy

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced submission of a supplemental New Drug Application (sNDA) to the U.

Rogers To Participate In CJS Summer Conference

Rogers To Participate In CJS Summer Conference

Rogers Corporation (NYSE:ROG) today announced President and CEO, Bruce Hoechner, will be presenting at the CJS 18 th Annual "New Ideas" Summer Investor Conference in White Plains, NY on Tuesday, July 10 at 8:40 am EDT.

Rogers Acquires Griswold LLC

Rogers Acquires Griswold LLC

Rogers Corporation (NYSE:ROG), a global leader in engineered material solutions, announced the acquisition of Griswold LLC, a leading manufacturer of custom-engineered cellular elastomer and high-performance polyurethane.

Phase III IMpassion130 Study Showed Genentech's TECENTRIQ Plus Abraxane Significantly Reduced The Risk Of Disease Worsening Or Death In People With Metastatic Or Locally Advanced Triple Negative Breast Cancer

Phase III IMpassion130 Study Showed Genentech's TECENTRIQ Plus Abraxane Significantly Reduced The Risk Of Disease Worsening Or Death In People With Metastatic Or Locally Advanced Triple Negative Breast Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMpassion130 study met its co-primary endpoint of progression free survival (PFS).

FDA Grants Priority Review To Genentech's Baloxavir Marboxil For The Treatment Of Influenza

FDA Grants Priority Review To Genentech's Baloxavir Marboxil For The Treatment Of Influenza

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

Genentech's TECENTRIQ In Combination With Chemotherapy Helped People With Previously-Untreated Extensive-Stage Small Cell Lung Cancer Live Significantly Longer Compared To Chemotherapy

Genentech's TECENTRIQ In Combination With Chemotherapy Helped People With Previously-Untreated Extensive-Stage Small Cell Lung Cancer Live Significantly Longer Compared To Chemotherapy

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMpower133 study met its co-primary endpoints of overall survival (OS) and progression-free survival (PFS) at its first interim analysis.

University Of Missouri School Of Medicine, Roche Collaborate On First US Implementation Of Tumor Board Software That Improves Treatment Decision Process For Cancer Patients

University Of Missouri School Of Medicine, Roche Collaborate On First US Implementation Of Tumor Board Software That Improves Treatment Decision Process For Cancer Patients

MU pilots Roche's cloud-based NAVIFY Tumor Board solution to streamline and standardize data collection and presentation, enabling faster, better collaboration among oncology care teams

Genentech Announces New OCREVUS (Ocrelizumab) Data On Long-Term Disability Benefits In Primary Progressive Multiple Sclerosis And Initiation Of Two Global Studies In Progressive MS

Genentech Announces New OCREVUS (Ocrelizumab) Data On Long-Term Disability Benefits In Primary Progressive Multiple Sclerosis And Initiation Of Two Global Studies In Progressive MS

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new OCREVUS ® (ocrelizumab) data will be presented at the 4 th Congress of the European Academy of Neurology (EAN) from June 16-19 in Lisbon, Portugal.

FDA Approves Genentech's Avastin (Bevacizumab) Plus Chemotherapy As A Treatment For Women With Advanced Ovarian Cancer Following Initial Surgery

FDA Approves Genentech's Avastin (Bevacizumab) Plus Chemotherapy As A Treatment For Women With Advanced Ovarian Cancer Following Initial Surgery

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

Roche Introduces First Self-testing Device For Warfarin Monitoring With Built In Bluetooth® Technology

Roche Introduces First Self-testing Device For Warfarin Monitoring With Built In Bluetooth® Technology

CoaguChek® Vantus system enables wireless reporting of INR results, making it easier for patients to accurately report their results.

Genentech Announces FDA Approval For Venclexta Plus Rituxan For People With Previously Treated Chronic Lymphocytic Leukemia

Genentech Announces FDA Approval For Venclexta Plus Rituxan For People With Previously Treated Chronic Lymphocytic Leukemia

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

FDA Approves Genentech's Rituxan (rituximab) For Pemphigus Vulgaris

FDA Approves Genentech's Rituxan (rituximab) For Pemphigus Vulgaris

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

Roche To Showcase New Solutions To Consolidate Automated Molecular Testing, Microbiology Topics From Industry Experts At ASM Microbe 2018

Roche To Showcase New Solutions To Consolidate Automated Molecular Testing, Microbiology Topics From Industry Experts At ASM Microbe 2018

-- CT/NG test, cobas omni Utility Channel offer IVD, LDT menu consolidation options for fully automated cobas 6800/8800 platform

Rogers Corporation Files Patent Infringement Lawsuit

Rogers Corporation Files Patent Infringement Lawsuit

Rogers Corporation (NYSE:ROG), today announced that its wholly owned subsidiary, Rogers Germany GmbH, has filed a patent infringement lawsuit in Dusseldorf, Germany against KCC Corporation of Seoul, Korea.

FDA Grants Priority Review To Genentech's HEMLIBRA (emicizumab-kxwh) For People With Hemophilia A Without Factor VIII Inhibitors

FDA Grants Priority Review To Genentech's HEMLIBRA (emicizumab-kxwh) For People With Hemophilia A Without Factor VIII Inhibitors

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

Phase III IMpower131 Study Showed Genentech's TECENTRIQ (Atezolizumab) Plus Chemotherapy (Carboplatin And ABRAXANE) Reduced The Risk Of Disease Worsening Or Death For People With Advanced Squamous Non-Small Cell Lung Cancer

Phase III IMpower131 Study Showed Genentech's TECENTRIQ (Atezolizumab) Plus Chemotherapy (Carboplatin And ABRAXANE) Reduced The Risk Of Disease Worsening Or Death For People With Advanced Squamous Non-Small Cell Lung Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that results from the Phase III IMpower131 study showed TECENTRIQ ® (atezolizumab) plus chemotherapy (carboplatin and ABRAXANE ® [albumin-bound paclitaxel;...

Phase III IMpower130 Study Showed Genentech's TECENTRIQ (Atezolizumab) Plus Chemotherapy (Carboplatin And ABRAXANE) Helped People With Metastatic Non-Squamous Non-Small Cell Lung Cancer Live Significantly Longer Compared To Chemotherapy Alone

Phase III IMpower130 Study Showed Genentech's TECENTRIQ (Atezolizumab) Plus Chemotherapy (Carboplatin And ABRAXANE) Helped People With Metastatic Non-Squamous Non-Small Cell Lung Cancer Live Significantly Longer Compared To Chemotherapy Alone

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMpower130 study met its co-primary endpoints of overall survival (OS) and progression-free survival (PFS).

Rogers To Participate In B. Riley FBR Investor Conference

Rogers To Participate In B. Riley FBR Investor Conference

Rogers Corporation (NYSE:ROG) today announced President and CEO, Bruce Hoechner, will be presenting at the 19 th Annual B.

Genentech's HEMLIBRA (emicizumab-kxwh) Reduced Treated Bleeds By 96 Percent Compared To No Prophylaxis In Phase III HAVEN 3 Study In Hemophilia A Without Factor VIII Inhibitors

Genentech's HEMLIBRA (emicizumab-kxwh) Reduced Treated Bleeds By 96 Percent Compared To No Prophylaxis In Phase III HAVEN 3 Study In Hemophilia A Without Factor VIII Inhibitors

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today full results from the Phase III HAVEN 3 study evaluating HEMLIBRA ® (emicizumab-kxwh) prophylaxis administered every week or every two weeks in people with hemophilia A...

Follow-up Phase III Data Showed Genentech's Alecensa Helped People With ALK-Positive Metastatic Non-Small Cell Lung Cancer Live A Median Of Almost Three Years Without Their Disease Worsening Or Death

Follow-up Phase III Data Showed Genentech's Alecensa Helped People With ALK-Positive Metastatic Non-Small Cell Lung Cancer Live A Median Of Almost Three Years Without Their Disease Worsening Or Death

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced follow-up data from the Phase III ALEX study, showing that as an initial treatment Alecensa ® (alectinib) significantly reduced the risk of disease progression or death...

Phase III IMpower150 Study Showed Genentech's TECENTRIQ And Avastin Plus Carboplatin And Paclitaxel Helped People With A Specific Type Of Metastatic Lung Cancer Live Significantly Longer Compared To Avastin Plus Carboplatin And Paclitaxel

Phase III IMpower150 Study Showed Genentech's TECENTRIQ And Avastin Plus Carboplatin And Paclitaxel Helped People With A Specific Type Of Metastatic Lung Cancer Live Significantly Longer Compared To Avastin Plus Carboplatin And Paclitaxel

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive results from the Phase III IMpower150 study of TECENTRIQ ® (atezolizumab) and Avastin ® (bevacizumab) plus carboplatin and paclitaxel (chemotherapy) for the...

FDA Approves Subcutaneous Formulation Of Actemra For Use In Active Polyarticular Juvenile Idiopathic Arthritis (PJIA), A Rare Form Of Juvenile Arthritis

FDA Approves Subcutaneous Formulation Of Actemra For Use In Active Polyarticular Juvenile Idiopathic Arthritis (PJIA), A Rare Form Of Juvenile Arthritis

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

FDA Approves Additional Claim For Roche Cobas Zika Test

- New claim allows for streamlined screening of pooled blood or plasma donations

Genentech To Present New Phase III Data For HEMLIBRA (emicizumab-kxwh) In People With Hemophilia A At The World Federation Of Hemophilia 2018 World Congress

Genentech To Present New Phase III Data For HEMLIBRA (emicizumab-kxwh) In People With Hemophilia A At The World Federation Of Hemophilia 2018 World Congress

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that Phase III results for HEMLIBRA ® (emicizumab-kxwh) will be presented for the first time during the World Federation of Hemophilia (WFH) 2018 World Congress from May...

Genentech Provides Update On Phase III Study Of TECENTRIQ (Atezolizumab) And COTELLIC (Cobimetinib) In People With Heavily Pre-Treated Locally Advanced Or Metastatic Colorectal Cancer

Genentech Provides Update On Phase III Study Of TECENTRIQ (Atezolizumab) And COTELLIC (Cobimetinib) In People With Heavily Pre-Treated Locally Advanced Or Metastatic Colorectal Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMblaze370 study evaluating the combination of TECENTRIQ ® (atezolizumab) and COTELLIC ® (cobimetinib) did not meet its primary endpoint of overall...

Genentech To Present New Data From Its Industry-Leading Oncology Portfolio At The 2018 American Society Of Clinical Oncology (ASCO) Annual Meeting

Genentech To Present New Data From Its Industry-Leading Oncology Portfolio At The 2018 American Society Of Clinical Oncology (ASCO) Annual Meeting

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new data from early and late-stage clinical studies on more than 19 approved and investigational cancer medicines, will be presented at the 2018 American Society of...

Rogers To Participate In Oppenheimer Industrial Growth Conference

Rogers To Participate In Oppenheimer Industrial Growth Conference

Rogers Corporation (NYSE:ROG) today announced President and CEO, Bruce Hoechner, will be presenting at the Oppenheimer 13 th Annual Industrial Growth Conference in New York City on Wednesday, May 9 at 8:55 am EDT.

FDA Grants Priority Review To Genentech's Cancer Immunotherapy TECENTRIQ (Atezolizumab) For Initial Treatment Of People With A Specific Type Of Metastatic Lung Cancer

FDA Grants Priority Review To Genentech's Cancer Immunotherapy TECENTRIQ (Atezolizumab) For Initial Treatment Of People With A Specific Type Of Metastatic Lung Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

TheStreet Quant Rating: B (Buy)